Identification of the risk factors for development of CMV virema associated with low dose Valganciclovir prophylaxis in obese kidney transplant recipients

Trial Profile

Identification of the risk factors for development of CMV virema associated with low dose Valganciclovir prophylaxis in obese kidney transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top